Brown R A, Farmer J B, Hall J C, Humphries R G, O'Connor S E, Smith G W
Br J Pharmacol. 1985 Jul;85(3):609-19. doi: 10.1111/j.1476-5381.1985.tb10555.x.
The cardiovascular effects of dopexamine and dopamine were compared in the anaesthetized and conscious dog by the use of intravenous infusions over the dose range 3 X 10(-9) - 10(-7)mol kg-1 min-1. In the anaesthetized dog, dopexamine produced a dose-related fall in blood pressure due to peripheral vasodilatation and a small rise in heart rate and contractility. By contrast, dopamine did not significantly reduce blood pressure but produced a larger dose-related increase in contractility. At the highest infusion rate (10(-7)mol kg-1 min-1) blood pressure and heart rate were increased by dopamine. Dopexamine dilated the renal and mesenteric vascular beds with a potency similar to that of dopamine. Femoral vascular responses produced by both agents were inconsistent but the highest infusion rate of dopamine did produce vasoconstriction. With the aid of selective receptor antagonists (haloperidol, propranolol and bulbocapnine) the vasodepressor activity of dopexamine was shown to be mediated by stimulation of DA2-, beta- and DA1-receptors. The cardiac stimulation and renal vasodilatation produced by both compounds were due to stimulation of beta-adrenoceptors and DA1-receptors respectively. In the conscious dog, intravenous infusion of dopexamine caused a dose-related fall in blood pressure, renal vasodilatation and an increase in cardiac contractility and heart rate. Dopamine also increased cardiac contractility, and renal blood flow due to renal vasodilatation but without affecting heart rate. At the highest infusion rate, blood pressure was increased. Dopexamine and dopamine produced a similar incidence of panting and repetitive licking at 3 X 10(-8)mol kg-1 min-1 and emesis at 10(-7)mol kg-1 min-1, due to stimulation of dopamine receptors in the chemoreceptor trigger zone. Dopexamine produces a different cardiovascular profile from dopamine in the anaesthetized and conscious dog. Both compounds reduce renal vascular resistance, but in contrast to dopamine, dopexamine reduces afterload and produces only mild inotropic stimulation. These differences reflect contrasting activity at adrenoceptors.
通过在3×10⁻⁹ - 10⁻⁷mol kg⁻¹ min⁻¹剂量范围内静脉输注,比较了多培沙明和多巴胺对麻醉和清醒犬心血管系统的影响。在麻醉犬中,多培沙明由于外周血管扩张导致血压呈剂量相关性下降,心率和心肌收缩力略有升高。相比之下,多巴胺不会显著降低血压,但会使心肌收缩力呈更大的剂量相关性增加。在最高输注速率(10⁻⁷mol kg⁻¹ min⁻¹)时,多巴胺会使血压和心率升高。多培沙明扩张肾和肠系膜血管床的效力与多巴胺相似。两种药物引起的股血管反应不一致,但多巴胺的最高输注速率确实会引起血管收缩。借助选择性受体拮抗剂(氟哌啶醇、普萘洛尔和千金藤素),多培沙明的血管舒张降压活性被证明是由DA₂、β和DA₁受体的刺激介导的。两种化合物引起的心脏刺激和肾血管舒张分别是由于β肾上腺素能受体和DA₁受体的刺激。在清醒犬中,静脉输注多培沙明导致血压呈剂量相关性下降、肾血管舒张以及心肌收缩力和心率增加。多巴胺也会增加心肌收缩力,并由于肾血管舒张而增加肾血流量,但不影响心率。在最高输注速率时,血压会升高。在3×10⁻⁸mol kg⁻¹ min⁻¹时,多培沙明和多巴胺引起气喘和反复舔舐的发生率相似,在10⁻⁷mol kg⁻¹ min⁻¹时引起呕吐,这是由于化学感受器触发区多巴胺受体的刺激。在麻醉和清醒犬中,多培沙明产生的心血管作用与多巴胺不同。两种化合物都降低肾血管阻力,但与多巴胺不同的是,多培沙明降低后负荷,仅产生轻度的变力性刺激。这些差异反映了肾上腺素能受体的不同活性。